Tiffany Seagroves, MBA, PhD, PMP

Tiffany N. Seagroves, PhD, MBA, PMP is a Full Professor of Medicine with tenure in the Tulane School of Medicine. She is the director of the Cancer Biology program in the Tulane Cancer Center, and co-lead for the Cancer Biology program for the Louisiana Cancer Research Center (LCRC). Her laboratory studies the biology of and therapeutic options for metastatic breast cancer using a variety of pre-clinical models.

Dr. Tiffany Seagroves completed her PhD degree in cell and molecular biology in 1998 from Baylor College of Medicine in the laboratory of Dr. Jeffrey M. Rosen. She received her MBA degree in marketing and food and drug regulatory affairs in 2003 at San Diego State University while completing a postdoctoral fellowship at UCSD with Dr. Randall S. Johnson. She was recruited to Tulane in July of 2024 after serving as faculty at the University of Tennessee Health Science Center (UTHSC) in Memphis, TN since 2005, where she was promoted from Assistant to Associate Professor with tenure in 2012 and to Full Professor in 2019. She served as the Associate Vice Chancellor for Research at UTHSC from 2015-2024, overseeing all institutional-level shared resource facilities. She earned her Project Management Professional (PMP) certification in 2023. 

Dr. Seagroves’ current research interests are understanding the biology of genes that regulate the hypoxic response to promote metastasis and characterizing the safety and efficacy of novel colchicine-binding site tubulin inhibitors (CBSIs) that bypass taxane resistance in collaboration with Drs. Wei Li and Duane Miller at UTHSC. Her laboratory curates several pre-clinical models of metastatic breast cancer, including syngeneic murine models, traditional human cell line xenograft models, and patient-derived xenograft (PDX) models. She also co-manages the newly launched Tulane Cancer Center/LCRC organoid analysis core. Dr. Seagroves is an Associate Editor for Breast Cancer Research and serves on multiple grant review panels for foundations, the Department of Defense, and the National Cancer Institute.